## CURES WITHIN REACH RESEARCHER SPOTLIGHT: A REVOLUTIONARY FOR HUNTINGTON'S DISEASE

In 2019, Cures Within Reach funded **Dr. Erin Furr Stimming** at **UTHealth Houston** and her clinical trial using Nuedexta, a drug for pseudobulbar affect, to tackle irritability in Huntington's disease patients.

Dr. Furr Stimming is currently a Professor with McGovern Medical School at UTHealth Houston and the Director of its Neurology Clerkship Program. She previously served as Chief of Neurology at Harris Health Lyndon B. Johnson Hospital in Houston, TX.

Dr. Furr Stimming is well respected for her 20 years of strong patient care, as well as her outstanding roles in research. Since 2016, she is the Director of the designated Level 2 Huntington's Disease Society of America Centers of Excellence in Houston. In addition to Huntington's disease, her clinical interests include Parkinson's disease, atypical parkinsonian syndromes, focal and generalized dystonia, essential tremors, and spasticity.

Her professional goal is to optimize quality of life outcomes for patients with Huntington's disease by delaying the progression of symptoms, as well as educating the community at large about Huntington's disease and current treatment options.



Erin Furr Stimming, MD
Professor and Memorial
Hermann Chair,
Department of Neurology
UTHealth Houston

## **PROFILE**

Dr. Erin Furr Stimming is a distinguished clinician and researcher, specializing in neurology and psychiatry.

## **CWR FUNDING**

- This now-completed \$100,000 Phase 2 clinical trial tested the use of a neurological drug for the treatment of irritability in patients with Huntington's disease.
- Dr. Furr Stimming and her trial represent two of Cures Within Reach's communities:
  - Neurology
  - Rare Diseases



Cures Within Reach leverages the speed, safety and cost-effectiveness by testing approved therapies for new indications, driving more treatments to more patients more quickly.